Search research articles
Contact Us
Filters
Showing results (131-140 of 344) with videos related to
Page
of 35
Sort By:
Nature Reviews. Clinical Oncology
|
May 15, 2026
Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons
Hongcheng Zhu, Florian Lordick, Yelena Y Janjigian, et al.
BMC Cancer
|
July 15, 2016
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study
Pashtoon M Kasi, Daisuke Kotani, Michael Cecchini, et al.
BMC Cancer
|
February 2, 2018
A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
Hiroshi Matsumoto, Akihito Kawazoe, Kaoru Shimada, et al.
Clinical Colorectal Cancer
|
January 3, 2016
Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution
Daisuke Kotani, Kohei Shitara, Akihito Kawazoe, et al.
Anti-Cancer Drugs
|
August 20, 2015
Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors
Toshihiko Doi, Takayuki Yoshino, Kohei Shitara, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
October 16, 2012
Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer
Chihiro Kondoh, Daisuke Takahari, Kohei Shitara, et al.
Gastrointestinal Cancer Research : GCR
|
December 15, 2010
Chemotherapy for patients with advanced gastric cancer with performance status 2
Kohei Shitara, Kei Muro, Keitaro Matsuo, et al.
Therapeutic Advances in Medical Oncology
|
May 7, 2021
Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
Keigo Chida, Daisuke Kotani, Yoshiaki Nakamura, et al.
Future Oncology (London, England)
|
August 24, 2022
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
Josep Tabernero, Lin Shen, Elena Elimova, et al.
Gastrointestinal Cancer Research : GCR
|
February 2, 2012
Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy
Kohei Shitara, Keitaro Matsuo, Tomoya Yokota, et al.
Page
of 35
Search research articles
Search
Showing results (131-140 of 344) with videos related to
Sort By:
Page
of 35
Nature Reviews. Clinical Oncology
|
May 15, 2026
Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons
Hongcheng Zhu, Florian Lordick, Yelena Y Janjigian, et al.
BMC Cancer
|
July 15, 2016
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study
Pashtoon M Kasi, Daisuke Kotani, Michael Cecchini, et al.
BMC Cancer
|
February 2, 2018
A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
Hiroshi Matsumoto, Akihito Kawazoe, Kaoru Shimada, et al.
Clinical Colorectal Cancer
|
January 3, 2016
Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution
Daisuke Kotani, Kohei Shitara, Akihito Kawazoe, et al.
Anti-Cancer Drugs
|
August 20, 2015
Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors
Toshihiko Doi, Takayuki Yoshino, Kohei Shitara, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
October 16, 2012
Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer
Chihiro Kondoh, Daisuke Takahari, Kohei Shitara, et al.
Gastrointestinal Cancer Research : GCR
|
December 15, 2010
Chemotherapy for patients with advanced gastric cancer with performance status 2
Kohei Shitara, Kei Muro, Keitaro Matsuo, et al.
Therapeutic Advances in Medical Oncology
|
May 7, 2021
Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
Keigo Chida, Daisuke Kotani, Yoshiaki Nakamura, et al.
Future Oncology (London, England)
|
August 24, 2022
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
Josep Tabernero, Lin Shen, Elena Elimova, et al.
Gastrointestinal Cancer Research : GCR
|
February 2, 2012
Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy
Kohei Shitara, Keitaro Matsuo, Tomoya Yokota, et al.
Page
of 35